Interview: Wettbewerber ziehen zurück, die Sanofi-Chefin sagt: „Es ist schlicht logisch, in Deutschland zu investieren“
Fast die gesamte Pharmabranche hat dem Kanzler eine Absage erteilt. Nur Sanofi-Chefin Belén Garijo kam zum Investitionsgipfel der Regierung – mit einer klaren Forderung an Friedrich Merz.
Sanofi CEO Belén Garijo recently attended the "Invest in Germany" conference in Berlin, expressing her belief in Germany as a strategic location for the company. Garijo stated that Sanofi is investing two billion euros in an insulin production facility in Frankfurt, which she called the "largest investment in our history." She emphasized that Germany is the company's third-largest market in terms of employees and production, and that the company has a significant presence and expertise in the insulin business.
Garijo explained that her competitors are pulling out of Germany, but Sanofi sees it as "logically" investing there due to the country's strategic importance, strong employment, and production. She also noted that other European pharmaceutical companies are investing in the US and China, but the majority of Sanofi's production sites remain in Europe.
Garijo highlighted the importance of innovation and thanked the German government and the EU for their support, stating that Europe needs an environment that promotes innovation and that Sanofi is working to attract additional investments.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
